Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer. RIBOLARIS
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SOLTI
- Phase: III
- Execution start: 17/12/2021
- End of execution: 28/02/2030
- IP: ISABEL BLANCAS LOPEZ-BARAJAS